Last mentioned: 1d ago
Across the most recent 7 stories covering Amgen — 29% positive, 71% neutral sentiment, averaging 6.1/10 impact.
This entity profile aggregates every story where the entity meets our minimum relevance threshold before it is linked here — a story naming this entity only in passing, as competitive context for an unrelated subject, does not qualify. That threshold exists because earlier testing surfaced entity pages cluttered with tangential mentions: a story about two unrelated companies merging could otherwise populate a third company's page simply because it was named once for comparison, with no real event of its own. The timeline below reflects genuine milestones and developments specific to this entity, cross-referenced against the same source-verification standard applied to every story on this site. Sentiment measures the directional read of each development for this entity specifically, not the overall tone of the reporting, and impact weights how consequential a development is rather than how widely it was syndicated across outlets.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
FDA approves Merck's Lipfendra
The FDA approves Lipfendra, the first oral PCSK9 inhibitor, under the expedited review program for high-risk statin-treated patients.
Marty Makary resigns as FDA Commissioner
Former FDA chief Dr. Marty Makary, who created the expedited drug review pathway, resigns amid political pressure.
Q4 2025 Preview
Analysts set expectations for oncology-driven revenue growth.
Loqtorzi Launch
Full commercial ramp-up of the first-in-class PD-1 for NPC.
Yusimry Divestiture
Sale of adalimumab biosimilar to HK King-Friend for $40M.
Cimerli Divestiture
Coherus sells its ranibizumab biosimilar to Sandoz for $170M.
Copay accumulator programs are shifting thousands in drug costs back to patients, causing financial distress and potential treatment delays. Larry Gruber’s experience with Oscar Health highlights the human toll of insurance practices that prioritize cost over care.
The FDA approval of Merck's Lipfendra introduces an oral alternative to injectable PCSK9 inhibitors, promising easier patient access and potential cost savings for health systems managing high cholesterol.
Source: mynbc5.com · wjcl.com
The FDA approved the first oral PCSK9 inhibitor, Lipfendra, demonstrating a 59% LDL reduction in trials. The pill form removes injection barriers and is priced lower than existing injectables, potentially improving adherence and access for patients with high cholesterol.
Amgen and NovoCure represent two extremes in healthcare delivery: a wholesale-dependent drug giant and a patient-centric device innovator. The comparison reveals how direct-to-patient models are reshaping oncology treatment accessibility and reimbursement dynamics.
Hong Kong's enterprise scheme is drawing major health firms like Amgen and Pfizer, valued at over $191.5 billion combined, to expand operations and drive innovation in biotechnology. This influx could enhance local health IT infrastructure and research capabilities, while also raising questions about regulatory alignment with global health standards. For healthcare professionals, this represents opportunities in clinical advancements and talent development amid increasing regional competition.
Source: Connor Mycroft (cn) · Connor Mycroft (hk)
Coherus BioSciences is set to report Q4 2025 results, marking a critical milestone in its transition from a biosimilar-focused firm to an innovative oncology leader. Investors are closely monitoring the commercial ramp of Loqtorzi and the market share gains of the Udenyca On-Body Injector following significant portfolio divestitures.
A growing movement in cardiovascular care is challenging the 'prescribe-first' mentality of statin therapy, emphasizing patient autonomy and shared decision-making. As clinical guidelines evolve, the healthcare industry is grappling with how to balance standardized protocols with individualized patient preferences and risk profiles.
Source: theobserver.ca · clintonnewsrecord.com
This page surfaces every story mentioning Amgen across our healthcare coverage. We track each entity's appearance over time so readers can trace how the narrative evolves — which developments are isolated incidents, which build into longer arcs, and which reframe how operators in the space think about the entity. Story selection uses the same multi-source verification gate applied across the rest of our coverage.
Read our editorial methodology for how we identify, deduplicate, and score entity references. Our glossary defines the technical terms used across stories on this page, and our trends index contextualizes individual developments against the longer-running healthcare beat. Cross-entity comparisons live on our compare view.
Entities only appear on this page once the classifier scores them at a minimum 35 percent relevance to the story, filtering out passing mentions. According to that methodology, reviewed July 2026, this follows multi-source corroboration standards recommended by journalism research bodies such as the Reuters Institute for the Study of Journalism.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
| What you see | What it tells you |
|---|---|
| Story count | Number of distinct stories where Amgen was a primary or referenced actor. |
| Recency clustering | Whether mentions are concentrated in a recent window (a news cycle) or distributed (a sustained arc). |
| Sentiment distribution | Aggregate sentiment of the stories mentioning this entity, weighted by impact score. |
| Cross-niche links | When the same entity surfaces in our sibling networks, we link to those views to enrich context. |